/PRNewswire/ CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration.
CollPlant Biotechnologies Provides Business Updates and Second Quarter 2021 Financial Results prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
BOULDER Biodesix Inc. (Nasdaq: BDSX) has agreed to build a companion test for HiberCell Inc. as the latter takes its breast cancer drug candidates through clinical trials.
In a statement, the Boulder-based Biodesix said it and New York City-based HiberCell will co-develop the test to determine suitable candidates for HiberCell’s candidate treatments for hibernating or relapsed breast cancer.
Financial terms of the deal were not disclosed.
The collaboration marks Biodesix’s entry into developing tests for a new part of the body. The company historically has focused on developing tests that help doctors of lung cancer patients determine the best modes of treatment; last year it partnered with Bio-Rad Laboratories Inc. (NYSE: BIO) to launch COVID-19 active infection and antibody tests.